Lifevantage Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Lifevantage Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Jun 30, 2018 | $203.20M | Aug 15, 2018 |
| FY2018 | Jun 30, 2017 | $199.49M | Aug 15, 2018 |
| FY2018 | Jun 30, 2016 | $206.54M | Aug 15, 2018 |
| FY2017 | Jun 30, 2015 | $190.34M | Sep 7, 2017 |
| FY2016 | Jun 30, 2014 | $213.97M | Dec 12, 2016 |
| FY2015 | Jun 30, 2013 | $208.18M | Sep 1, 2015 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $228.53M | Sep 4, 2025 |
| FY2025 | Jun 30, 2024 | $200.16M | Sep 4, 2025 |
| FY2024 | Jun 30, 2023 | $213.40M | Aug 28, 2024 |
| FY2022 | Jun 30, 2022 | $50.94M | Aug 23, 2022 |
| FY2022 | Mar 31, 2022 | $50.00M | Aug 23, 2022 |
| FY2022 | Dec 31, 2021 | $52.19M | Aug 23, 2022 |
| FY2022 | Sep 30, 2021 | $53.22M | Aug 23, 2022 |
| FY2022 | Jun 30, 2021 | $54.78M | Aug 23, 2022 |
| FY2022 | Mar 31, 2021 | $51.57M | Aug 23, 2022 |
| FY2022 | Dec 31, 2020 | $59.01M | Aug 23, 2022 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Jun 30, 2018 | $54.03M | Aug 15, 2018 |
| FY2018 | Mar 31, 2018 | $50.56M | Aug 15, 2018 |
| FY2018 | Dec 31, 2017 | $49.48M | Aug 15, 2018 |
| FY2018 | Sep 30, 2017 | $49.13M | Aug 15, 2018 |
| FY2018 | Jun 30, 2017 | $50.64M | Aug 15, 2018 |
| FY2018 | Mar 31, 2017 | $45.01M | Aug 15, 2018 |
| FY2018 | Dec 31, 2016 | $48.95M | Aug 15, 2018 |
| FY2018 | Sep 30, 2016 | $54.89M | Aug 15, 2018 |
| FY2017 | Jun 30, 2016 | $53.03M | Sep 7, 2017 |
| FY2017 | Mar 31, 2016 | $56.16M | Sep 7, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $183.67M | Sep 4, 2025 |
| FY2025 | Jun 30, 2024 | $158.72M | Sep 4, 2025 |
| FY2024 | Jun 30, 2023 | $170.01M | Aug 28, 2024 |
| FY2022 | Jun 30, 2022 | $41.61M | Aug 23, 2022 |
| FY2022 | Mar 31, 2022 | $40.35M | Aug 23, 2022 |
| FY2022 | Dec 31, 2021 | $42.51M | Aug 23, 2022 |
| FY2022 | Sep 30, 2021 | $43.79M | Aug 23, 2022 |
| FY2022 | Jun 30, 2021 | $45.00M | Aug 23, 2022 |
| FY2022 | Mar 31, 2021 | $42.75M | Aug 23, 2022 |
| FY2022 | Dec 31, 2020 | $48.82M | Aug 23, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $9.81M | Sep 4, 2025 |
| FY2025 | Jun 30, 2024 | $2.94M | Sep 4, 2025 |
| FY2024 | Jun 30, 2023 | $2.54M | Aug 28, 2024 |
| FY2022 | Jun 30, 2022 | ($1.42M) | Aug 23, 2022 |
| FY2022 | Mar 31, 2022 | $1.14M | Aug 23, 2022 |
| FY2022 | Dec 31, 2021 | $79.0K | Aug 23, 2022 |
| FY2022 | Sep 30, 2021 | $3.32M | Aug 23, 2022 |
| FY2022 | Jun 30, 2021 | $4.91M | Aug 23, 2022 |
| FY2022 | Mar 31, 2021 | $1.72M | Aug 23, 2022 |
| FY2022 | Dec 31, 2020 | $3.81M | Aug 23, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $12.20M | Sep 4, 2025 |
| FY2025 | Jun 30, 2024 | $4.33M | Sep 4, 2025 |
| FY2024 | Jun 30, 2023 | $4.26M | Aug 28, 2024 |
| FY2023 | Jun 30, 2022 | $7.58M | Aug 28, 2023 |
| FY2022 | Jun 30, 2021 | $17.62M | Aug 23, 2022 |
| FY2022 | Jun 30, 2020 | $15.47M | Aug 23, 2022 |
| FY2021 | Jun 30, 2019 | $9.81M | Aug 19, 2021 |
| FY2020 | Jun 30, 2018 | $10.32M | Aug 18, 2020 |
| FY2019 | Jun 30, 2017 | $4.45M | Aug 14, 2019 |
| FY2018 | Jun 30, 2016 | $13.41M | Aug 15, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $1.40M | Sep 4, 2025 |
| FY2025 | Jun 30, 2024 | $700.0K | Sep 4, 2025 |
| FY2024 | Jun 30, 2023 | $600.0K | Aug 28, 2024 |
| FY2023 | Jun 30, 2022 | $700.0K | Aug 28, 2023 |
| FY2022 | Jun 30, 2021 | $700.0K | Aug 23, 2022 |
| FY2022 | Jun 30, 2020 | $900.0K | Aug 23, 2022 |
| FY2021 | Jun 30, 2019 | $1.10M | Aug 19, 2021 |
| FY2020 | Jun 30, 2018 | $1.20M | Aug 18, 2020 |
| FY2019 | Jun 30, 2017 | $1.10M | Aug 14, 2019 |
| FY2018 | Jun 30, 2016 | $1.00M | Aug 15, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $69.21M | Sep 4, 2025 |
| FY2025 | Jun 30, 2024 | $68.47M | Sep 4, 2025 |
| FY2024 | Jun 30, 2023 | $71.07M | Aug 28, 2024 |
| FY2023 | Jun 30, 2022 | $63.43M | Aug 28, 2023 |
| FY2022 | Jun 30, 2021 | $60.84M | Aug 23, 2022 |
| FY2022 | Jun 30, 2020 | $67.91M | Aug 23, 2022 |
| FY2021 | Jun 30, 2019 | $69.55M | Aug 19, 2021 |
| FY2020 | Jun 30, 2018 | $59.84M | Aug 18, 2020 |
| FY2019 | Jun 30, 2017 | $64.92M | Aug 14, 2019 |
| FY2018 | Jun 30, 2016 | $56.07M | Aug 15, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $11.88M | Sep 4, 2025 |
| FY2025 | Jun 30, 2024 | $12.20M | Sep 4, 2025 |
| FY2024 | Jun 30, 2023 | $6.83M | Aug 28, 2024 |
| FY2023 | Jun 30, 2022 | $7.96M | Aug 28, 2023 |
| FY2022 | Jun 30, 2021 | $16.27M | Aug 23, 2022 |
| FY2022 | Jun 30, 2020 | $18.33M | Aug 23, 2022 |
| FY2021 | Jun 30, 2019 | $17.79M | Aug 19, 2021 |
| FY2020 | Jun 30, 2018 | $13.26M | Aug 18, 2020 |
| FY2019 | Jun 30, 2017 | $6.60M | Aug 14, 2019 |
| FY2018 | Jun 30, 2016 | $6.04M | Aug 15, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $1.37M | Sep 4, 2025 |
| FY2025 | Jun 30, 2024 | $2.25M | Sep 4, 2025 |
| FY2024 | Jun 30, 2023 | $3.07M | Aug 28, 2024 |
| FY2023 | Jun 30, 2022 | $1.53M | Aug 28, 2023 |
| FY2022 | Jun 30, 2021 | $3.74M | Aug 23, 2022 |
| FY2022 | Jun 30, 2020 | $2.68M | Aug 23, 2022 |
| FY2021 | Jun 30, 2019 | $2.51M | Aug 19, 2021 |
| FY2020 | Jun 30, 2018 | $4.65M | Aug 18, 2020 |
| FY2019 | Jun 30, 2017 | $1.06M | Aug 14, 2019 |
| FY2018 | Jun 30, 2016 | $562.0K | Aug 15, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $71.96M | Sep 4, 2025 |
| FY2025 | Jun 30, 2024 | $60.30M | Sep 4, 2025 |
| FY2024 | Jun 30, 2023 | $66.12M | Aug 28, 2024 |
| FY2023 | Jun 30, 2022 | $70.71M | Aug 28, 2023 |
| FY2022 | Jun 30, 2021 | $78.73M | Aug 23, 2022 |
| FY2021 | Jun 30, 2020 | $58.88M | Aug 19, 2021 |
| FY2020 | Jun 30, 2019 | $55.27M | Aug 18, 2020 |
| FY2019 | Jun 30, 2018 | $51.14M | Aug 14, 2019 |
| FY2018 | Jun 30, 2017 | $45.25M | Aug 15, 2018 |
| FY2017 | Jun 30, 2016 | $50.86M | Sep 7, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $37.32M | Sep 4, 2025 |
| FY2025 | Jun 30, 2024 | $34.31M | Sep 4, 2025 |
| FY2024 | Jun 30, 2023 | $31.47M | Aug 28, 2024 |
| FY2023 | Jun 30, 2022 | $39.19M | Aug 28, 2023 |
| FY2022 | Jun 30, 2021 | $41.93M | Aug 23, 2022 |
| FY2021 | Jun 30, 2020 | $25.62M | Aug 19, 2021 |
| FY2020 | Jun 30, 2019 | $28.07M | Aug 18, 2020 |
| FY2019 | Jun 30, 2018 | $29.20M | Aug 14, 2019 |
| FY2018 | Jun 30, 2017 | $30.72M | Aug 15, 2018 |
| FY2017 | Jun 30, 2016 | $40.21M | Sep 7, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $34.64M | Sep 4, 2025 |
| FY2025 | Jun 30, 2024 | $25.99M | Sep 4, 2025 |
| FY2025 | Jun 30, 2023 | $34.65M | Sep 4, 2025 |
| FY2024 | Jun 30, 2022 | $31.52M | Aug 28, 2024 |
| FY2023 | Jun 30, 2021 | $36.81M | Aug 28, 2023 |
| FY2022 | Jun 30, 2020 | $33.25M | Aug 23, 2022 |
| FY2022 | Jun 30, 2019 | $27.20M | Aug 23, 2022 |
| FY2019 | Jul 1, 2018 | $21.94M | Aug 14, 2019 |
| FY2021 | Jun 30, 2018 | $21.95M | Aug 19, 2021 |
| FY2020 | Jun 30, 2017 | $14.53M | Aug 18, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($104.15M) | Sep 4, 2025 |
| FY2025 | Jun 30, 2024 | ($108.74M) | Sep 4, 2025 |
| FY2024 | Jun 30, 2023 | ($98.31M) | Aug 28, 2024 |
| FY2023 | Jun 30, 2022 | ($98.44M) | Aug 28, 2023 |
| FY2022 | Jun 30, 2021 | ($92.35M) | Aug 23, 2022 |
| FY2021 | Jun 30, 2020 | ($93.31M) | Aug 19, 2021 |
| FY2020 | Jun 30, 2019 | ($99.96M) | Aug 18, 2020 |
| FY2019 | Jun 30, 2018 | ($102.73M) | Aug 14, 2019 |
| FY2018 | Jun 30, 2017 | ($106.99M) | Aug 15, 2018 |
| FY2017 | Jun 30, 2016 | ($108.60M) | Sep 7, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $20.20M | Sep 4, 2025 |
| FY2025 | Jun 30, 2024 | $16.89M | Sep 4, 2025 |
| FY2024 | Jun 30, 2023 | $21.61M | Aug 28, 2024 |
| FY2023 | Jun 30, 2022 | $20.19M | Aug 28, 2023 |
| FY2022 | Jun 30, 2021 | $23.17M | Aug 23, 2022 |
| FY2021 | Jun 30, 2020 | $22.14M | Aug 19, 2021 |
| FY2020 | Jun 30, 2019 | $18.82M | Aug 18, 2020 |
| FY2019 | Jun 30, 2018 | $16.65M | Aug 14, 2019 |
| FY2018 | Jun 30, 2017 | $11.46M | Aug 15, 2018 |
| FY2018 | Jun 30, 2016 | $7.88M | Aug 15, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 0 | Sep 4, 2025 |
| FY2025 | Jun 30, 2024 | 0 | Sep 4, 2025 |
| FY2024 | Jun 30, 2023 | 0 | Aug 28, 2024 |
| FY2022 | Jun 30, 2022 | 0 | Aug 23, 2022 |
| FY2022 | Mar 31, 2022 | 0 | Aug 23, 2022 |
| FY2022 | Dec 31, 2021 | 0 | Aug 23, 2022 |
| FY2022 | Sep 30, 2021 | 0 | Aug 23, 2022 |
| FY2022 | Jun 30, 2021 | 0 | Aug 23, 2022 |
| FY2022 | Mar 31, 2021 | 0 | Aug 23, 2022 |
| FY2022 | Dec 31, 2020 | 0 | Aug 23, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 0 | Sep 4, 2025 |
| FY2025 | Jun 30, 2024 | 0 | Sep 4, 2025 |
| FY2024 | Jun 30, 2023 | 0 | Aug 28, 2024 |
| FY2022 | Jun 30, 2022 | 0 | Aug 23, 2022 |
| FY2022 | Mar 31, 2022 | 0 | Aug 23, 2022 |
| FY2022 | Dec 31, 2021 | 0 | Aug 23, 2022 |
| FY2022 | Sep 30, 2021 | 0 | Aug 23, 2022 |
| FY2022 | Jun 30, 2021 | 0 | Aug 23, 2022 |
| FY2022 | Mar 31, 2021 | 0 | Aug 23, 2022 |
| FY2022 | Dec 31, 2020 | 0 | Aug 23, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 12.43M | Sep 4, 2025 |
| FY2025 | Jun 30, 2024 | 12.51M | Sep 4, 2025 |
| FY2024 | Jun 30, 2023 | 12.62M | Aug 28, 2024 |
| FY2023 | Jun 30, 2022 | 12.49M | Aug 28, 2023 |
| FY2022 | Jun 30, 2021 | 13.61M | Aug 23, 2022 |
| FY2021 | Jun 30, 2020 | 14.31M | Aug 19, 2021 |
| FY2020 | Jun 30, 2019 | 14.11M | Aug 18, 2020 |
| FY2019 | Jun 30, 2018 | 14.07M | Aug 14, 2019 |
| FY2018 | Jun 30, 2017 | 14.23M | Aug 15, 2018 |
| FY2017 | Jun 30, 2016 | 14.03M | Sep 7, 2017 |